TRex Bio (NASDAQ:TRXB) Now Covered by Analysts at Evercore

Equities research analysts at Evercore assumed coverage on shares of TRex Bio (NASDAQ:TRXB) in a report issued on Tuesday, Zacks reports. The firm set a “strong-buy” rating on the stock.

A number of other analysts have also commented on TRXB. JPMorgan Chase & Co. assumed coverage on shares of TRex Bio in a research note on Tuesday. They set an “overweight” rating and a $20.00 price objective for the company. Stifel Nicolaus began coverage on shares of TRex Bio in a research report on Tuesday. They issued a “buy” rating and a $39.00 target price on the stock. Cantor Fitzgerald assumed coverage on shares of TRex Bio in a report on Tuesday. They set an “overweight” rating on the stock. Finally, Wedbush assumed coverage on shares of TRex Bio in a research report on Monday. They issued an “outperform” rating and a $30.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $29.67.

TRex Bio Stock Down 1.3%

NASDAQ:TRXB opened at $13.55 on Tuesday. TRex Bio has a 1-year low of $12.50 and a 1-year high of $16.56.

Insider Buying and Selling at TRex Bio

In other TRex Bio news, major shareholder Alexandria Venture Investments purchased 178,571 shares of the stock in a transaction dated Tuesday, October 13th. The shares were acquired at an average price of $14.00 per share, for a total transaction of $2,499,994.00. Following the completion of the acquisition, the insider owned 1,346,501 shares of the company’s stock, valued at $18,851,014. This represents a 15.29% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

About TRex Bio

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.